New site established in collaboration with a government agency to bolster spider silk output and market readiness

ANN ARBOR, Mich., August 4, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. This milestone marks the launch of the first full production cycle at the site. This production site was secured earlier this summer through an agreement with a government agency in Southeast Asia.

This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the Company’s growth strategy as it prepares for anticipated product deliveries to potential customers and strategic markets.

This inaugural production cycle will include the rearing of the Company’s parent lines for its BAM-1 spider silk hybrid, as well as several new transgenic lines that were introduced into the production environment in the first half of 2025. These next-generation strains are part of the Company’s ongoing development pipeline. These new strains are expected to complement the existing BAM-1 hybrids while delivering higher silk yields, improved silk quality, and enhanced robustness.

“This facility represents a critical step forward in our production capabilities,” said Founder and CEO of Kraig Labs, Kim Thompson. “Our collaboration with government agencies in the region has created a robust platform for sustainable growth, allowing us to expand our operational footprint while maintaining close control over the quality and consistency of our spider silk.”

Kraig Labs expects this production cycle to lay the groundwork for future expansion and delivery readiness of the highest-grade fibers as it continues scaling its proprietary silk technology.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Improved processing unlocks greater quality and efficiency for recombinant spider silk fiber

ANN ARBOR, Mich., August 4, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the recent successful production of reeled raw recombinant spider silk using automated equipment. This batch set a new single run record, processing more than 250 kilograms of spider silk cocoons and represents a major step forward in improving the quality, yield, and scalability of spider silk production.

The use of automated reeling equipment allows Kraig Labs to fine-tune and adapt the reeling process specifically for the unique properties of spider silk, compared to traditional silkworm silk. By modifying machine settings, reeling speeds, and temperatures, the team is optimizing fiber consistency and maximizing silk output. These improvements are critical in translating the natural strength and elasticity of spider silk into finished materials for commercial applications.

“This successful automated reeling run demonstrates our ability to enhance fiber quality, adapting existing production capacity for spider silk manufacturing,” said Jon Rice, COO of Kraig Labs. “Our team is making continuous refinements to tailor the reeling equipment for spider silk, and we’re already seeing how those adjustments lead to better, more consistent fibers.”

Automated reeling replaces conventional multi-end systems, significantly improving throughput, labor efficiency, and downstream silk quality. The compatibility of Kraig Labs’ proprietary spider silk cocoons with these advanced systems is central to the Company’s effort to build a vertically integrated production model for spider silk at scale.

This achievement builds upon recent operational momentum, including the expansion of rearing capacity in Asia and the development of new spider silk strains. Together, these advances support the Company’s broader mission to bring high-performance, eco-friendly spider silk fibers to market.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., July 28, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the formal signing of a multi-year agreement with a government agency in Southeast Asia to support the scale-up of its recombinant spider silk production.

This agreement is the result of many years of groundwork by Kraig Labs and marks a significant step in the Company’s ongoing efforts to commercialize next-generation biomaterials. Under the terms of the agreement, Kraig Labs will gain access to government-supported rearing facilities, technical personnel, and infrastructure critical to accelerating production and expanding operational capacity.

“This milestone reflects many years of work by our senior management and on-the-ground team,” said COO of Kraig Labs, Jon Rice. “With the support of this agreement, we are now positioned to move more quickly and efficiently toward large-scale commercialization.”

Kraig Labs expects to take possession of the new facility and initiate operations in early August.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Newly Deployed Strains Deliver Strong Performance in Initial Field Rearing Cycles, Paving the Way for Accelerated Deployment of Next-Generation Transgenics

ANN ARBOR, Mich., July 21, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest recombinant spider silk production strains. These newly developed strains were transitioned from the Company’s R&D program into field production earlier this quarter and have now completed their first rearing cycle, delivering strong performance across key production metrics.

This successful lab-to-field transition marks a critical milestone in the Company’s strategy to rapidly deploy advanced spider silk genetics into its operational model. All three new strains demonstrated excellent vitality and a strong alignment with large-scale production targets. These initial results validate the Company’s development pipeline and underscore the scalability of its enhanced fiber engineering platform.

“This achievement demonstrates not only the power of our new transgenic lines but also the speed with which Kraig Labs can move innovations from concept to production,” said Jon Rice, COO of Kraig Labs. “With these new strains already in cocoon, we are now focused on rapidly expanding egg inventories through July and preparing for a second rearing cycle starting in early August.”

The three strains now entering the cocoon stage represent the latest step in the Company’s broader production roadmap. Kraig Labs is aggressively ramping up its egg multiplication efforts, which will supply the next generation of production cycles and integrate these powerful new lines into the Company’s commercial operations. The successful launch of these strains provides strong proof of concept for future generations of even more advanced transgenic silks, currently under development.

“These early results are a powerful signal of what’s ahead,” Rice continued. “As we continue to build the world’s first cost-effective and scalable spider silk production platform, this milestone sets the stage for deploying our most advanced technologies into the field with speed and confidence.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., July 18, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to expand the scale and security of its recombinant spider silk manufacturing platform.

This landmark agreement, expected to be signed before the end of July, marks the culmination of years of relationship-building and demonstrated performance by Kraig Labs and its proprietary spider silk technologies. The agreement is designed to accelerate the Company’s growth by providing access to previously unavailable rearing facilities, supporting infrastructure, and technical resources.

Under the terms of this collaboration, Kraig Labs will work closely with government specialists to optimize and expand spider silk production. The collaboration will unlock new production capacity, enabling Kraig Labs to significantly scale its hybridized silkworm operations.

Importantly, this agreement also includes provisions for the creation of parallel rearing operations, a key component in the Company’s long-term roadmap to mitigate production risk and eliminate single points of failure. By distributing parent strain and egg production across multiple independent facilities, Kraig Labs is further securing its supply chain and increasing throughput capacity to meet future demand.

“We believe this collaboration is a transformative step forward in our mission to commercialize sustainable, cost-effective spider silk. This rare opportunity is due, in large part, to the team we’ve assembled, our commitment to excellence, and our progress in the field,” said the Company’s COO, Jon Rice. “It provides us with strategic infrastructure and institutional support to grow our production footprint, while further reinforcing the stability and security of our operations through parallelized rearing and egg development systems.”

Work under this agreement is anticipated to begin in August. This collaboration will serve as a foundational element of the Company’s expanding global spider silk manufacturing strategy, highlighting the growing confidence in the Company’s pioneering biomaterials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

New Architecture lays foundation for Higher Output, continuous Batch Production, and prepares Company for Spider Silk delivery to European-based Global Luxury Market Leader

ANN ARBOR, Mich., July 14, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”, “Kraig”, or “Kraig Labs”), a world leader in spider silk technology*, announces the addition of a second parallel production facility, three new advanced spider silk strains, and the immediate launch of a new diapausing system for production. This marks three critical advancements in the Company’s high-performance spider silk manufacturing and commercialization to significantly increase production yields and spun silk quality.

Jon Rice, COO of Kraig Labs, recently traveled to the Company’s production facilities in Southeast Asia to organize the launch of this next exciting phase of Kraig’s production plan for 2025 and 2026, including a second, parallel production facility, three new spider silk strains, and a shift to controlled diapause for production.

A central part of these advancements is the adoption of a second parallel rearing center. A lease for the second facility is being finalized, and parental strain rearing is expected to begin there within the next 30 days.

Kraig Labs completed the development of three new spider silk strains, which are now in the field. These strains, developed over the last year, were designed to complement the Company’s existing BAM-1 hybrid by improving hybrid vigor and increasing silk yield. One of these stains was designed as a replacement for an existing BAM-1 parent lines. Two of these strains were bred to produce silkworms suitable for controlled diapause.

Diapause refers to the silkworm’s natural wintering period, a process which can be replicated with a 90-day cold treatment of the silkworm eggs. Diapausing silkworm strains are the gold standard for producing premium silk. One of the Company’s key initial target customers is a widely-renowned producer of the world’s finest fabrics and garments, crafted from the highest-quality fibers. Kraig Labs is committed to meeting those standards with its spider silk and the shift to diapausing egg production, along with the addition of a second facility, are key drivers in achieving that goal and increasing production.

Thus far, the Company’s production center has operated under a batch production model, bypassing diapause and limiting production to 8 or 9 batches per year. The shift to parallel facilities and the diapausing of eggs (artificial wintering utilizing cold storage treatment) will enable nearly continuous production. These two facilities will operate in tandem to feed that production. While egg production from one facility enters cold storage, the second facility will prepare the next rearing cycle, ensuring a continuous flow of eggs to supply production operations. This new collaborative production system will dramatically expand production capacity far beyond what any single facility could produce independently.

As Kraig Labs rolls out these significant improvements to its operations, the Company is undertaking a production transition period, which includes a 90-day cold treatment cycle for the new diapausing hybrid eggs. This wintering process is widely recognized for yielding stronger, finer silk and significantly larger cocoons than non-diapausing silk. Over the next several months, operational emphasis will shift away from finished silk production and focus on expanding parent line populations and generating the next round of hybrid eggs that Kraig Labs plans to begin releasing in the fourth quarter.

“Deploying two separate rearing centers for our parent lines is a key part of our strategy to build a reliable and scalable supply chain that can address the demand for spider silk and support year-round production,” said Kim Thompson, Founder and CEO of Kraig Labs. “This plan, which is the brainchild of our chief sericulture expert, Dr. Kumar, will provide the throughput necessary to support large-scale commercial production and a buffer against potential disruption.”

In parallel with these advancements in production operations, Kraig Labs is pleased to announce it has completed the latest batch of BAM-1 finished spider silk. With this newest batch of finished silk complete, the Company has now accumulated approximately one-third of the total spider silk required to fulfill a material request from a globally renowned European fashion house.

“This latest batch brings us another step closer to delivering premium spider silk materials to one of the most recognized names in fashion. The shift to a diapausing hybrid system reflects our long-term vision to deliver the highest quality spider silk at commercial scale,” said Rice. “By making this investment in time, infrastructure, and production strategy, we are positioning ourselves to meet the demand we see forming.”

Today’s announcement marks a significant milestone in Kraig’s commercialization roadmap, accelerating the Company’s goal of establishing the world’s first cost-effective, environmentally responsible spider silk production platform. The transition to diapausing hybrid rearing and parallel rearing operations enhances supply chain resilience and long-term throughput, as Kraig Labs responds to growing interest from industry.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., June 10, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces that senior management will travel to Southeast Asia this week to oversee the continued expansion of the Company’s recombinant spider silk production operations.

This strategic visit is designed to support and accelerate the Company’s 2025 production scale-up. In addition to reinforcing partnerships with current production collaborators, Kraig Labs leadership will evaluate options to onboard additional rearing capacity, including private partnerships and potential collaborations to further expand its manufacturing footprint.

This trip was scheduled in coordination with Dr. Nirmal Kumar, the Company’s lead sericulture expert. Dr. Kumar’s expertise and guidance have been instrumental in developing and executing the Company’s production expansion initiatives and optimizing the deployment of its proprietary spider silk technologies in the field.

In addition to meetings with key partners, senior management will review current spider silk inventories in preparation for anticipated shipments to strategic customers later this year. This review highlights the Company’s commitment to upholding high standards of quality and readiness as it progresses toward fulfilling commercial orders.

“Our continuing expansion in Southeast Asia has been one of the highlights of this year,” said Jon Rice, COO of Kraig Labs. “This trip will build on that success, allowing management to work side-by-side with our team and partners to continue strengthening the future of spider silk production. We are incredibly proud of what we’ve accomplished so far in 2025, and we look forward to taking the next steps during this trip to grow production and prepare for the upcoming commercial deliveries.”

The Company’s momentum in scaling up production reflects its broader mission to bring sustainable, high-performance spider silk materials to market and establish a robust commercial supply chain.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., June 3, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, issues a letter to shareholders.

Dear Shareholders,

We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week’s announcement of the development of the new production strain and the potential for commercial deliveries in 2025.

The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world’s first development on schedule. This and many of our other laboratory announcements are not only significant; they’re foundational technology building blocks to our success.

Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders.

We are no longer experiencing the robustness challenges we faced with single-strain rearing. Before the rollout of the BAM-1 hybrid in 2024, our silkworms lacked the robustness to deal with the silkworm diseases and environmental stress that are frequently present in the field. In terms of robustness and disease tolerance, the BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk.    

Now, this doesn’t mean that we are invincible. Globally, between 10% to 30% of all silk production with robust double hybrids is lost due to a handful of diseases and adverse weather conditions. This is just a part of working with these living production systems. It is a fact that is reflected in global silk economics. Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid. Right now, the region’s sericulture operators are in their rainy season, which is typically the worst time for silkworm rearing. Production of our BAM-1 strains and production of mundane silk producers utilizing Chinese hybrids are negatively impacted during this cycle. That is a normal part of silkworm rearing and is something that all silkworm producers encounter as a normal part of the business.

In the past, before we introduced BAM-1, the effects on our silkworms were significantly magnified and effectively stymied our growth. In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory. As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further.

Regarding inventory calculation, our current inventory figures track finished raw reeled silk. In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk. The reason inventory did not increase in our financial report was because that report tracked finished silk or material form. After considering these questions, and in light of the fact that we are moving from nominal inventory to larger scale production, we will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled. You can expect us to begin adding completed recombinant spider silk cocoon to our WIP to all future inventory balances. 

We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we’ve been able to move faster to deliver on that commitment. As a great example, we are in regular communication with three major Global brands that are standing by to receive their first shipments of materials. The first is an internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs. The second is a world leader in high-end performance sportswear with an approved budget to buy silk from us. The third is one of the world’s top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production. Currently, we expect to begin deliveries to these customers in the second half of this year. That will be a significant milestone for Kraig Labs, our shareholders, and material science.

I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support.

Kim Thompson, CEO

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production.

ANN ARBOR, Mich., May 28, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production.

This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales.

“Our team continues to deliver on key milestones as we scale the commercialization of spider silk,” said Company Founder and CEO, Kim Thompson. “With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double-hybrid production system.”

This latest strain is part of Kraig Labs’ broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model, expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs.

“As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency,” Thompson continued. “This is a key step forward in our mission to bring the power of spider silk to mainstream markets.”

The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

New Location to Support Unprecedented 2025 Spider Silk Production Expansions

ANN ARBOR, Mich., May 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*,  announces today that it has officially received its business license to begin operations in the Kingdom of Cambodia. This milestone marks a significant step in the Company’s ongoing strategy to scale up and diversify its production capabilities in response to the exceptional success of its 2025 expansion initiatives.

The Company’s decision to launch operations in Cambodia is grounded in the continued positive momentum Kraig Labs has achieved through its expanded production efforts this year.

“This license represents more than just geographic growth—it’s a reflection of the strong foundation we’ve built through our 2025 production expansion,” said Jon Rice, COO of Kraig Labs. “Cambodia offers the right combination of climate, infrastructure, and opportunity to support the next phase of our spider silk production scale up. We are confident that this new location will play a role in helping continue to grow and diversity our production based for our spider silk materials.”

The Cambodian business license is expected to support the Company’s goals of increasing production capacity, while simultaneously diversifying its production footprint. As Kraig Labs embarks on this next phase of its business plan, it continues to invest in both research and infrastructure to advance the performance and scalability of its proprietary recombinant spider silk technologies.

Kraig Labs remains committed to strengthening its production pipeline and establishing a global footprint that supports the commercial roll-out of next-generation biomaterials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com